You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
In the quarter T2 signed a licensing agreement for SARS-CoV-2 assay development and a purchasing agreement with Vizient.
The company's Diagnostics segment was down 2 percent year over year, while its Discovery & Analytical Solutions segment grew 2 percent.
NG Biotech's COVID-19 NG-Test IgG-IgM test detects and differentiates the presence of isotypes IgG and IgG antibodies to SARS-CoV-2.
Both RT-PCR tests are designed to detect SARS-CoV-2 nucleic acid in nasal swabs, although Sansure's test can be used with other respiratory specimens.
The added funds will be used by Tangen to develop a molecular diagnostic platform to detect anthrax in the bloodstream and develop infectious disease tests.
The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.
The test will be included in the World Health Organizations list of prequalified in vitro diagnostics and UN agencies will be able to procure it.
The drugmaker will cover the cost of testing for up to 500 patients in the US with MSI-high colorectal cancer or RAI-refractory differentiated thyroid cancer.
Asia revenue fell 22 percent year over year, primarily due to a slowdown of testing in China as a result of the COVID-19 pandemic, the company said.
SG Blocks said it intends to create SARS-CoV-2 testing facilities using its expertise in building structures from maritime-grade shipping containers.
The firm said it anticipates introducing an antibody test for its high-throughput analyzers that will detect an immune response to the coronavirus.
The firms have already completed proof-of-concept studies for their semiconductor biosensor chips and Roswell plans to have the initial chips by 2021.
The Euroimmun's Anti-SARS-CoV-2 ELISA test is the first serology test whose results were independently validated by the federal government.
The company's revenue growth was driven by increasing sales of its ePlex molecular diagnostics analyzer, which now has a SARS-CoV-2 test.
The firm's first quarter molecular diagnostics revenues were up 28 percent over Q1 2019 to $45.2 million.
Fulgent saw a 75 percent increase year over year in billable tests, leading to revenues of $7.8 million. It also withdrew its 2020 full-year revenue guidance.
Although the firm said it refocused its business strategy to address the need for COVID-19 tests in Q1, product sales fell 14 percent year over year.
The agency will now require commercial antibody test manufacturers to meet certain sensitivity and specificity thresholds.
Among the study's aims is determining how rates of SARS-CoV-2 infection differ between healthy children and ones with asthma or other allergic conditions.
Busulfan is a chemotherapeutic used as conditioning agent prior to hematopoietic stem cell transplants, which are used in Avrobio's investigational therapies.
The triplex assay can be used on the firm's QX200 or QXDx Droplet Digital PCR systems to process 93 patient samples per run.
Starting in late May, Hologic expects to begin producing at least 1 million Aptima SARS-CoV-2 assays per week, BARDA noted.
The panel is designed to detect and differentiate between nucleic acids from SARS-CoV-2 and 20 other viral and bacterial respiratory pathogens.
Wadsworth's test detects antibodies against SARS-CoV-2 in serum, while Altru Diagnostics' test detects viral nucleic acid in respiratory specimens.
The rapid automated RT-PCR test detects SARS-CoV-2 from nasopharyngeal, oropharyngeal, or nasal swab specimens and runs on NeuMoDx's Molecular Systems.